亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

美國領(lǐng)先仿生有限公司（Advanced Bionics）   
2009年11月9日美國唯一生產(chǎn)人工耳蝸的專業(yè)公司美國領(lǐng)先仿生有限公司（Advanced Bionics）宣布和瑞士Sonova集團(tuán)達(dá)成并購協(xié)議。
美國領(lǐng)先仿生有限公司（Advanced Bionics）是全球領(lǐng)先的從事人工耳蝸的研發(fā)生產(chǎn)和技術(shù)創(chuàng)新的專業(yè)公司，公司的總部位于美國加州洛杉磯生物科學(xué)園。 　　
　　上個(gè)世紀(jì)80年代，加利福尼亞大學(xué)的舊金山分校的科學(xué)家獨(dú)立開發(fā)出了新型號(hào)的多通道人工耳蝸，Alfred E.Mann先生和該校洽談后獲得該技術(shù)，于1993年出資創(chuàng)建了美國領(lǐng)先仿生公司。

　　作為人工耳蝸領(lǐng)域的創(chuàng)新者，秉持“病人至上、品質(zhì)第一”的服務(wù)宗旨，依托美國領(lǐng)先的電子技術(shù)和全球范圍內(nèi)的研究中心，美國領(lǐng)先仿生有限公司擁有的最多的人工耳蝸?zhàn)詫＠夹g(shù)，我們以其強(qiáng)大的技術(shù)實(shí)力和銳意創(chuàng)新能力，成為該領(lǐng)域無可爭議的領(lǐng)導(dǎo)者。

我們的領(lǐng)先歷史： 我們的使命：

第一個(gè)提供設(shè)計(jì)多個(gè)程序存儲(chǔ)空間的聲音處理器。
第一個(gè)提供音量和靈敏度控制。
第一個(gè)提供環(huán)抱耳蝸軸的電極陣列。
第一個(gè)提供可充電電池技術(shù)。
第一個(gè)提供不同聲音處理策略的選擇能力。
第一個(gè)提供自然的麥克風(fēng)位置。
第一個(gè)，并且是唯一的提供多個(gè)電極同時(shí)刺激。
第一個(gè)，并且是唯一的提供高分辨率聲音策略。
第一個(gè)能夠引發(fā)神經(jīng)隨機(jī)響應(yīng)的正常聽覺反應(yīng)方式。
第一個(gè)提供通道定向技術(shù)。
第一個(gè)提供120個(gè)通道。
第一個(gè)同Phonak SmartLink藍(lán)牙系統(tǒng)兼容
......
　　創(chuàng)新和研發(fā)可植入的仿生技術(shù)使得患神經(jīng)疾病的人們能克服自身的障礙，改善他們的生活，使聾者復(fù)聰、盲者復(fù)明、跛者復(fù)行！


執(zhí)行總裁Jeff Grainer這樣描述公司：
　　“我們正在努力建立這樣一個(gè)公司，在這里，產(chǎn)品可靠性是最永遠(yuǎn)放在第一位的，創(chuàng)新開發(fā)和進(jìn)入市場的時(shí)間是我們成功的關(guān)鍵，任何想象豐富的念頭都受到鼓勵(lì)，紀(jì)律和團(tuán)隊(duì)工作是我們的組織成分，我們的員工懂得一起投身于一項(xiàng)有意義的事業(yè)，他們工作的使命就是：改善他人的生活！” 
        
Advanced Bionics? Corporation is a global leader in developing the most reliable, best performing cochlear implant devices in the world. Founded in 1993, AB is the only American company developing cutting-edge cochlear implant technology that restores hearing to the deaf and allows our recipients to hear their best today, tomorrow, and always. We support patients, clinicians, and physicians through the latest scientific research, technology development, educational resources, attentive customer service, community involvement, and more.

AB evolved from two highly successful companies that developed and marketed innovative medical devices; one created new generation pacemakers, and the other developed microinfusion systems (miniature drug delivery pumps used in the treatment of diabetes). Our talented group of technologists and professionals from all over the world are driven to succeed, work with integrity, and stay firmly committed to quality.

Today, AB remains dedicated to improving lives by developing, manufacturing, and distributing the world’s most reliable, best performing cochlear implant system.

Our Mission
At AB, our mission is to improve lives by developing, manufacturing, marketing, and supporting high-quality, state-of-the-art hearing technology for those with severe to profound hearing loss.

Our commitment to providing the best possible hearing experience for our recipients by putting patients first remains at the forefront of all that we do. The trust our recipients place in us is the highest honor and inspires us to strive for excellence each and every day.

Our Culture
Our culture is best described by our people: highly intelligent, spirited, ambitious, and dedicated. We attract innovative technologists and distinguished professionals from all over the world who are committed to improving the lives of those with severe to profound hearing loss.

The culture of AB is shaped daily by our unique mission, the leaders who successfully drive the business, and the staff members from all across the globe who help our recipients hear their best.

"We are building a company with a culture where reliability matters most, where innovation and time to market are the keys to our financial success, where crazy ideas are encouraged, where discipline and teamwork are part of our fabric, and where our employees understand the privilege of being engaged together in a business whose mission is to improve the lives of others."

—Jeff Greiner, President and Co-Chief Executive Officer

Our Focus
At AB, we focus on putting patients first in everything that we do. As part of our firm commitment to patients, we’ve enacted eight core initiatives, each designed to improve the lives of our recipients on their journey to hearing with AB.

Reliability: Deliver reliable cochlear implant systems.
Improvements: Make improvements on ease of use and aesthetics of our cochlear implant systems.
Communicate Differences: Communicate the performance differences between devices.
Make It Easy: Make it easy for patients and clinicians to get what they need.
Reimbursement: Help patients and clinicians access appropriate insurance reimbursement.
Legacy Patients: Support legacy patients throughout their journey to hearing.
Global Company: Address the needs of our patients across the world.
Lifelong Partner: Remain reasonably profitable in order to be a lifelong partner to our recipients.
Leadership
Jeff Greiner
President and Chief Executive Officer
A lawyer by training and an Air Force Academy graduate, Jeff Greiner has been the operational leader of Advanced Bionics? from its beginning.

He served a commitment to the Air Force as part of the Judge Advocate General’s Department. He left the Air Force in 1986 and became the Associate General Counsel for Siemens-Pacesetter and the Acting General Counsel for MiniMed Technologies, Limited, the predecessor entity which produced both MiniMed, Inc. and Advanced Bionics Corporation.

In 1992, Mr. Greiner left Siemens-Pacesetter to lead and build AB into a leading neurological device company. He has grown the company from seven employees in 1992 to over 600 employees in 2009 with an emphasis on leadership and the creation of an innovative and spirited culture, where creativity and discipline are the keys to producing exceptional technology that improves lives.

He holds a B.S. degree in Economics with highest honors from the United States Air Force Academy (1974), a JD degree from UCLA (1977), and an LLM with highest honors from George Washington University (1985).

Al Mann
Chairman and Founder
Alfred E. Mann serves as Chairman of the Board and CEO of MannKind Corporation, a diversified biopharmaceutical company focused on the development of novel therapeutics and drug-delivery technologies for the treatment of diabetes, cancer, autoimmune, and inflammatory diseases. MannKind’s lead product mimics the insulin kinetics of a normal pancreas, creating a new therapy paradigm for diabetes. In 1993, Mr. Mann also founded and began serving as Chairman and co-CEO of Advanced Bionics Corporation (“"Bionics”).

Additionally, Mr. Mann founded and served as the Chairman of the Board and Chief Executive Officer of MiniMed, Inc. from its founding in 1993 until August 2001 when it was